Development status: Approved, off-patent

Gram-positive activity

Gram-negative activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Inhibits bacterial DNA-dependent RNA polymerase, thus inhibiting bacterial RNA synthesis

Additional information: Semisynthetic, derived from rifampicin, nonabsorbable. Used for the treatment of gastrointestinal infections (approved for traveler's diarrhea caused only by noninvasive E. coli, overt hepatic encephalopathy recurrence, irritable bowel syndrome with diarrhea)